$104 Million

ImmunoGen, Inc.

Follow-on Offering

Bookrunner, January 2020

ImmunoGen, Inc.
ImmunoGen, Inc. is a clinical stage biotechnology company focused on developing innovative antibody drug conjugate, or ADC, therapies for the targeted treatment of cancer.